Vigil Neuroscience Ownership
| VIGL Stock | USD 2.47 0.17 7.39% |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Vigil |
Vigil Stock Ownership Analysis
About 21.0% of the company outstanding shares are owned by insiders. The company has Price to Book (P/B) ratio of 1.14. Historically many companies with similar price-to-book (P/B) ratio do better than the market in the long run. Vigil Neuroscience recorded a loss per share of 2.07. The entity had not issued any dividends in recent years. Vigil Neuroscience, Inc., a microglia-focused company, engages in the development of disease-modifying therapeutics for patients, caregivers, and families affected by rare and common neurodegenerative diseases. Vigil Neuroscience, Inc. operates as a subsidiary of Amgen Inc. Vigil Neuroscience operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 48 people. For more information please call Ivana JD at 857 254 4445 or visit https://www.vigilneuro.com.Besides selling stocks to institutional investors, Vigil Neuroscience also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Vigil Neuroscience's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Vigil Neuroscience's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Vigil Neuroscience Quarterly Liabilities And Stockholders Equity |
|
About 21.0% of Vigil Neuroscience are currently held by insiders. Unlike Vigil Neuroscience's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Vigil Neuroscience's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Vigil Neuroscience's insider trades
Vigil Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Vigil Neuroscience is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Vigil Neuroscience backward and forwards among themselves. Vigil Neuroscience's institutional investor refers to the entity that pools money to purchase Vigil Neuroscience's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Pivotal Bioventure Partners Investment Advisor Llc | 2024-06-30 | 560.6 K | Rock Springs Capital Management Lp | 2024-06-30 | 472 K | Orbimed Advisors, Llc | 2024-06-30 | 448.9 K | Blackrock Inc | 2024-06-30 | 405 K | Goldman Sachs Group Inc | 2024-06-30 | 401.1 K | Millennium Management Llc | 2024-06-30 | 334.8 K | Arrowmark Colorado Holdings, Llc (arrowmark Partners) | 2024-09-30 | 289.5 K | Abrdn Plc | 2024-09-30 | 235 K | Geode Capital Management, Llc | 2024-09-30 | 226.1 K | Northpond Ventures, Llc | 2024-09-30 | 4.2 M | Artal Group S A | 2024-06-30 | 1.8 M |
Vigil Neuroscience Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Vigil Neuroscience insiders, such as employees or executives, is commonly permitted as long as it does not rely on Vigil Neuroscience's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Vigil Neuroscience insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Vigil Neuroscience Outstanding Bonds
Vigil Neuroscience issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Vigil Neuroscience uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Vigil bonds can be classified according to their maturity, which is the date when Vigil Neuroscience has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Viking Cruises Ltd Corp BondUS92676XAD93 | View | |
| Viking Cruises Ltd Corp BondUS92676XAC11 | View | |
| US92676XAF42 Corp BondUS92676XAF42 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View |
Vigil Neuroscience Corporate Filings
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
8K | 7th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F3 | 9th of October 2024 An amendment to the original Schedule 13D filing | ViewVerify |
13A | 12th of August 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out World Market Map to better understand how to build diversified portfolios, which includes a position in Vigil Neuroscience. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. For more information on how to buy Vigil Stock please use our How to buy in Vigil Stock guide.You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Vigil Neuroscience. If investors know Vigil will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Vigil Neuroscience listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.07) | Return On Assets (0.40) | Return On Equity (0.70) |
The market value of Vigil Neuroscience is measured differently than its book value, which is the value of Vigil that is recorded on the company's balance sheet. Investors also form their own opinion of Vigil Neuroscience's value that differs from its market value or its book value, called intrinsic value, which is Vigil Neuroscience's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Vigil Neuroscience's market value can be influenced by many factors that don't directly affect Vigil Neuroscience's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Vigil Neuroscience's value and its price as these two are different measures arrived at by different means. Investors typically determine if Vigil Neuroscience is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Vigil Neuroscience's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.